With efficacy that hit the primary endpoint but fell below what Wall Street watched for, Biocryst Pharmaceuticals Inc. hopes a sampling program and BCX-7353's oral route will help gain market share for the once-daily kallikrein inhibitor to prevent hereditary angioedema (HAE).